• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers.

作者信息

Boucly Athénaïs, Savale Laurent, Jaïs Xavier, Humbert Marc, Sitbon Olivier, Montani David

机构信息

School of Medicine Université Paris-Saclay Le Kremlin-Bicêtre France.

Department of Respiratory and Intensive Care Medicine, AP-HP Hôpital Bicêtre Le Kremlin-Bicêtre France.

出版信息

Pulm Circ. 2022 Mar 11;12(1):e12023. doi: 10.1002/pul2.12023. eCollection 2022 Jan.

DOI:10.1002/pul2.12023
PMID:35506076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9052987/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f894/9052987/b6500e1a4efa/PUL2-12-e12023-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f894/9052987/b6500e1a4efa/PUL2-12-e12023-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f894/9052987/b6500e1a4efa/PUL2-12-e12023-g001.jpg

相似文献

1
Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers.BMPR2 基因突变携带者使用肠外前列腺素的序贯联合治疗。
Pulm Circ. 2022 Mar 11;12(1):e12023. doi: 10.1002/pul2.12023. eCollection 2022 Jan.
2
Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.遗传性肺动脉高压伴 BMPR2 突变患者的血液动力学和临床发病情况。
Respir Res. 2011 Jul 29;12(1):99. doi: 10.1186/1465-9921-12-99.
3
Prevalence and clinical features of bone morphogenetic protein receptor type 2 mutation in Korean idiopathic pulmonary arterial hypertension patients: The PILGRIM explorative cohort.韩国特发性肺动脉高压患者骨形态发生蛋白受体 2 突变的患病率和临床特征：PILGRIM 探索性队列研究。
PLoS One. 2020 Sep 23;15(9):e0238698. doi: 10.1371/journal.pone.0238698. eCollection 2020.
4
BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension.骨形态发生蛋白受体2（BMPR2）突变在男性肺动脉高压患者中对表型的影响更为明显。
Circ Cardiovasc Genet. 2012 Oct 1;5(5):511-8. doi: 10.1161/CIRCGENETICS.111.962209. Epub 2012 Aug 25.
5
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.BMPR2 突变携带者的肺动脉高压临床结局
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1377-83. doi: 10.1164/rccm.200712-1807OC. Epub 2008 Mar 20.
6
Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.从肠外前列腺素到塞来昔帕用于肺动脉高压的转换经验。
J Cardiovasc Pharmacol. 2020 Apr;75(4):299-304. doi: 10.1097/FJC.0000000000000800.
7
BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.骨形态发生蛋白受体II（BMPRII）影响肺微血管内皮细胞对炎症介质的反应。
Pflugers Arch. 2016 Nov;468(11-12):1969-1983. doi: 10.1007/s00424-016-1899-1. Epub 2016 Nov 6.
8
Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.肺动脉高压患者中BMPR2、ACVRL1和KCNA5基因的新型突变与血流动力学参数
PLoS One. 2014 Jun 17;9(6):e100261. doi: 10.1371/journal.pone.0100261. eCollection 2014.
9
Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers.携带 BMPR2 和 ALK1 突变的儿童肺动脉高压的结局。
Am J Cardiol. 2012 Aug 15;110(4):586-93. doi: 10.1016/j.amjcard.2012.04.035. Epub 2012 May 25.
10
Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.性别和 BMPR2 突变类型对肺动脉高压临床表型无影响。
Respir Res. 2010 Jun 10;11(1):73. doi: 10.1186/1465-9921-11-73.

引用本文的文献

1
Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH.肺动脉高压的遗传咨询和检测：国际肺动脉高压遗传研究联盟的共识声明。
Eur Respir J. 2023 Feb 23;61(2). doi: 10.1183/13993003.01471-2022. Print 2023 Feb.

本文引用的文献

1
BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series.骨形态发生蛋白受体2（BMPR2）突变与吸入或胃肠外前列腺素类药物的反应：病例系列
Pulm Circ. 2021 Dec 6;11(4):20458940211037275. doi: 10.1177/20458940211037275. eCollection 2021 Oct-Dec.
2
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.初始治疗策略与肺动脉高压长期生存的关系。
Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC.
3
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.
肺动脉高压死亡率：2015 年欧洲肺动脉高压指南风险分层模型预测。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00740-2017. Print 2017 Aug.
4
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.BMPR2 突变与肺动脉高压患者生存：一项个体参与者数据荟萃分析。
Lancet Respir Med. 2016 Feb;4(2):129-37. doi: 10.1016/S2213-2600(15)00544-5. Epub 2016 Jan 19.
5
Genetic counselling in a national referral centre for pulmonary hypertension.肺高血压国家转诊中心的遗传咨询。
Eur Respir J. 2016 Feb;47(2):541-52. doi: 10.1183/13993003.00717-2015. Epub 2015 Dec 23.
6
Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.重度特发性、遗传性或食欲抑制剂相关性肺动脉高压患者目前使用依前列醇的情况：来自法国肺动脉高压注册研究的数据
Int J Cardiol. 2014 Apr 1;172(3):561-7. doi: 10.1016/j.ijcard.2013.12.313. Epub 2014 Jan 22.